Literature DB >> 22157650

Cardiac myosin binding protein C insufficiency leads to early onset of mechanical dysfunction.

Candida L Desjardins1, Yong Chen, Arthur T Coulton, Brian D Hoit, Xin Yu, Julian E Stelzer.   

Abstract

BACKGROUND: Decreased expression of cardiac myosin binding protein C (cMyBPC) as a result of genetic mutations may contribute to the development of hypertrophic cardiomyopathy (HCM); however, the mechanisms that link cMyBPC expression and HCM development, especially contractile dysfunction, remain unclear. METHODS AND
RESULTS: We evaluated cardiac mechanical function in vitro and in vivo in young mice (8-10 weeks of age) carrying no functional cMyBPC alleles (cMyBPC(-/-)) or 1 functional cMyBPC allele (cMyBPC(±)). Skinned myocardium isolated from cMyBPC(-/-) hearts displayed significant accelerations in stretch activation cross-bridge kinetics. Cardiac MRI studies revealed severely depressed in vivo left ventricular (LV) magnitude and rates of LV wall strain and torsion compared with wild-type (WT) mice. Heterozygous cMyBPC(±) hearts expressed 23±5% less cMyBPC than WT hearts but did not display overt hypertrophy. Skinned myocardium isolated from cMyBPC(±) hearts displayed small accelerations in the rate of stretch induced cross-bridge recruitment. MRI measurements revealed reductions in LV torsion and circumferential strain, as well reduced circumferential strain rates in early systole and diastole.
CONCLUSIONS: Modest decreases in cMyBPC expression in the mouse heart result in early-onset subtle changes in cross-bridge kinetics and in vivo LV mechanical function, which could contribute to the development of HCM later in life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22157650      PMCID: PMC3328136          DOI: 10.1161/CIRCIMAGING.111.965772

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  48 in total

1.  Myocardial tissue tracking with two-dimensional cine displacement-encoded MR imaging: development and initial evaluation.

Authors:  Daniel Kim; Wesley D Gilson; Christopher M Kramer; Frederick H Epstein
Journal:  Radiology       Date:  2004-01-22       Impact factor: 11.105

2.  Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging.

Authors:  Daniel B Ennis; Frederick H Epstein; Peter Kellman; Lameh Fananapazir; Elliot R McVeigh; Andrew E Arai
Journal:  Magn Reson Med       Date:  2003-09       Impact factor: 4.668

3.  Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice.

Authors:  Samantha P Harris; Christopher R Bartley; Timothy A Hacker; Kerry S McDonald; Pamela S Douglas; Marion L Greaser; Patricia A Powers; Richard L Moss
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

4.  A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance.

Authors:  J A Moolman; S Reith; K Uhl; S Bailey; M Gautel; B Jeschke; C Fischer; J Ochs; W J McKenna; H Klues; H P Vosberg
Journal:  Circulation       Date:  2000-03-28       Impact factor: 29.690

5.  Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice.

Authors:  Lucie Carrier; Ralph Knöll; Nicolas Vignier; Dagmar I Keller; Pedro Bausero; Bernard Prudhon; Richard Isnard; Marie-Lory Ambroisine; Marc Fiszman; John Ross; Ketty Schwartz; Kenneth R Chien
Journal:  Cardiovasc Res       Date:  2004-08-01       Impact factor: 10.787

6.  Role of cardiac myosin binding protein C in sustaining left ventricular systolic stiffening.

Authors:  Bradley M Palmer; Dimitrios Georgakopoulos; Paul M Janssen; Yuan Wang; Norman R Alpert; Diego F Belardi; Samantha P Harris; Richard L Moss; Patrick G Burgon; Christine E Seidman; J G Seidman; David W Maughan; David A Kass
Journal:  Circ Res       Date:  2004-04-01       Impact factor: 17.367

7.  Complementary displacement-encoded MRI for contrast-enhanced infarct detection and quantification of myocardial function in mice.

Authors:  Wesley D Gilson; Zequan Yang; Brent A French; Frederick H Epstein
Journal:  Magn Reson Med       Date:  2004-04       Impact factor: 4.668

8.  Effect of cardiac myosin binding protein-C on mechanoenergetics in mouse myocardium.

Authors:  Bradley M Palmer; Teruo Noguchi; Yuan Wang; John R Heim; Norman R Alpert; Patrick G Burgon; Christine E Seidman; J G Seidman; David W Maughan; Martin M LeWinter
Journal:  Circ Res       Date:  2004-05-20       Impact factor: 17.367

9.  Expression patterns of cardiac myofilament proteins: genomic and protein analysis of surgical myectomy tissue from patients with obstructive hypertrophic cardiomyopathy.

Authors:  Jeanne L Theis; J Martijn Bos; Jason D Theis; Dylan V Miller; Joseph A Dearani; Hartzell V Schaff; Bernard J Gersh; Steve R Ommen; Richard L Moss; Michael J Ackerman
Journal:  Circ Heart Fail       Date:  2009-05-13       Impact factor: 8.790

10.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.

Authors:  Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  13 in total

1.  The contribution of cardiac myosin binding protein-c Ser282 phosphorylation to the rate of force generation and in vivo cardiac contractility.

Authors:  Kenneth S Gresham; Ranganath Mamidi; Julian E Stelzer
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

Review 2.  Quantification of regional myocardial wall motion by cardiovascular magnetic resonance.

Authors:  Kai Jiang; Xin Yu
Journal:  Quant Imaging Med Surg       Date:  2014-10

3.  Phosphorylation of cMyBP-C affects contractile mechanisms in a site-specific manner.

Authors:  Li Wang; Xiang Ji; David Barefield; Sakthivel Sadayappan; Masakata Kawai
Journal:  Biophys J       Date:  2014-03-04       Impact factor: 4.033

4.  Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.

Authors:  Ranganath Mamidi; Kenneth S Gresham; Amy Li; Cristobal G dos Remedios; Julian E Stelzer
Journal:  J Mol Cell Cardiol       Date:  2015-06-20       Impact factor: 5.000

5.  Functional dissection of myosin binding protein C phosphorylation.

Authors:  Manish K Gupta; James Gulick; Jeanne James; Hanna Osinska; John N Lorenz; Jeffrey Robbins
Journal:  J Mol Cell Cardiol       Date:  2013-08-31       Impact factor: 5.000

6.  Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy.

Authors:  Ranganath Mamidi; Jiayang Li; Kenneth S Gresham; Julian E Stelzer
Journal:  Pflugers Arch       Date:  2013-12-06       Impact factor: 3.657

Review 7.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

8.  Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.

Authors:  David Barefield; Mohit Kumar; Pieter P de Tombe; Sakthivel Sadayappan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-24       Impact factor: 4.733

9.  Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere.

Authors:  Y Cheng; X Wan; T A McElfresh; X Chen; K S Gresham; D S Rosenbaum; M P Chandler; J E Stelzer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-10       Impact factor: 4.733

10.  In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice.

Authors:  Sergei Merkulov; Xiaoqin Chen; Margaret P Chandler; Julian E Stelzer
Journal:  Circ Heart Fail       Date:  2012-08-01       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.